Silexion Therapeutics Announces Selection of Contract Research Organization to Support Upcoming Phase 2/3 Clinical Trials for SIL204
(SIOX) Strategic CRO to Support Path to Phase 2/3 Trials Following Recently Demonstrated Groundbreaking 97% Inhibition Rates for SIL204
How does the 97% inhibition data for SIL204 compare to similar agents in the market, and what competitive advantage might it confer if the trials succeed?
What is the projected timeline for the Phase 2/3 data readout, and how could that timeline influence the stock's volatility and price targets?
How will the selection of the CRO and the upcoming Phase 2/3 trials affect SIOX's cash burn and financing needs in the near term?
8 days ago